The abstract is read at the publisher; the summary is JClub's.
Short-course dabrafenib plus trametinib restored iodine uptake within 2 weeks in 6 of 9 (67%) radioiodine-treated patients with MAPK-driven radioiodine-refractory thyroid carcinoma.
- Why it matters: MAPK pathway activation suppresses iodine-handling genes like NIS, limiting radioiodine avidity, and the time to maximal re-differentiation after BRAF/MEK inhibition was unclear.
- What they did: In a multicentre phase II trial of 14 patients with progressive metastatic radioiodine-refractory thyroid carcinoma harboring BRAFV600E or RAS mutations, I-124 PET/CT dosimetry was repeated after 2 weeks and again at week 4 if needed. Radioiodine was given once predicted lesional absorbed dose was ≥20 Gy with I-131 activity ≤300 mCi.
- The result: Among radioiodine-treated patients, the best objective response rate within 6 months was 75% by RECIST and median progression-free survival was 10.8 months; RAS-mutant tumors showed greater lesion regression than BRAFV600E-mutant tumors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.